Alnylam Pharmaceuticals (NQ: ALNY )

122.97 USD -0.35 (-0.28%)

Official Closing Price Updated: 4:07 PM EDT, Oct 30, 2020 Add to My Watchlist

Price and Volume

Volume	733,500
Open	122.80
Bid (Size)	118.04 (12)
Ask (Size)	145.00 (1)
Prev. Close	123.32
Today's Range	119.29 - 124.60
52wk Range	83.06 - 167.33
Shares Outstanding	100,522,411
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)

October 30, 2020

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biotechnology Product for ONPATTRO® (patisiran)....

Alnylam Named a Top Biopharma Employer by Science Magazine

October 29, 2020

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named the company a top employer in its...

Performance

YTD	+6.36%	+6.36%
1 Month	-15.54%	-15.54%
3 Month	-15.64%	-15.64%
6 Month	-4.65%	-4.65%
1 Year	+41.77%	+41.77%

More News

Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results

October 22, 2020

Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week

October 22, 2020

Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups

October 16, 2020

Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference

October 13, 2020

Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six

September 30, 2020

Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference

September 28, 2020

Notable Monday Option Activity: AX, ALNY, GME

October 26, 2020

Alnylam Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ALNY

October 23, 2020

12 Healthcare Stocks Moving In Thursday's After-Market Session

October 22, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.